Across TCGA pan-cancer cohorts, C22orf34 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated C22orf34 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher C22orf34 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated C22orf34 expression acts as an unfavorable survival marker.

KICH, COAD, and UCEC are the cancer types where C22orf34 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
COAD	OS	Median	II,III,IV	0.168	0.788	.005	8	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: C22orf34 tumor-vs-normal RNA expression · all C22orf34 data types